Standard-of-care treatment seems to be harmful to early-stage CRC patients with high PD-L1 expression (HR = 4.95; CI, 1.10–22.35), suggesting that standard chemotherapy should not be used in stage II/III colorectal carcinoma patients with PD-L1 (high)/MSI/immune (high) (113). This evidence concerns the gene CD274 and colorectal carcinoma.